Analyst Scoreboard: 5 Ratings For Axonics
Portfolio Pulse from Benzinga Insights
Five analysts have provided ratings on Axonics (NASDAQ:AXNX) with diverse perspectives ranging from bullish to bearish. Over the last three months, there have been 2 bullish and 3 somewhat bullish ratings, with no changes in the past 30 days. The average 12-month price target is $70.0, with a high of $75.00 and a low of $63.00, marking a decrease from the previous average of $75.25. Analysts from Truist Securities, Piper Sandler, Morgan Stanley, Needham, and Leerink Partners have adjusted their price targets and ratings, reflecting their views on the company's performance and market conditions. Axonics, a medical technology company, has shown a revenue growth of 32.27% as of September 30, 2023, and has a market capitalization below the industry average. It also boasts a net margin of 4.22%, ROE of 0.65%, ROA of 0.6%, and a debt-to-equity ratio of 0.0.
January 09, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Axonics has received diverse analyst ratings, with an average 12-month price target of $70.0, down from the previous $75.25. The company has shown strong financial performance with significant revenue growth and solid profitability metrics.
The mixed analyst ratings and the lowered price target suggest a neutral short-term impact on Axonics' stock price. The strong financial performance could counterbalance the reduced price target, leading to a potentially stable outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100